News

EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema

The study results will help to identify dosing levels for future clinical trials

The partnership will further the effort to bring VGX-0111, a gene therapy treatment for AMD to patients and providers.

A Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, the Eagle is intended for use in performing selective laser trabeculoplasty.

Ophthalmology witnessed a transformative year with 12 FDA approvals. As the year concludes, there remains a robust pipeline of drugs, setting high expectations for continued advancements in ophthalmological care in 2024 and beyond.

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for diabetic macular edema.

The treatment option can have a positive impact on quality of life for patients.

The system hopes to use optical coherence tomography (OCT), while at the same time, leverage air and ultrasonic pulses to excite the mechanical waves in the cornea, enabling the detection of normotensive glaucoma.

The company’s lead ophthalmology candidate, EXN407, has the potential to be the first topical treatment for DR/DME.

TP-03 (lotilaner ophthalmic solution, 0.25%) was approved by the FDA in 2023 under the brand name Xdemvy for the treatment of Demodex blepharitis and s being evaluated as an investigational therapy for the treatment of Meibomian Gland Disease (MGD) in patients with Demodex mites.

ROP can be a disease that affects both the retinal and choroidal vasculatures.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD.

Orbis advances cataract surgery training in low-resource areas with technology

The drug is being evaluated on its safety, tolerability and pharmacokinetics of intravitreal single-rising doses and multiple doses as a potential treatment for GA.

Japanese investigators may have found a way of predicting which patients will develop intraocular inflammation in retrospective study.

According to the company, the device is designed to offer a non-surgical solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.

David A. Eichenbaum, MD, highlighted new therapies such as faricimab and high-dose aflibercept to reduce the burden of diseases like macular degeneration and diabetic eye conditions while improving patient outcomes during his presentation at EyeCon 2023.

MACs categorize goniotomy, canaloplasty, cyclophotocoagulation as experimental; glaucoma specialists speak out.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD, but this research more clearly shows how cells are affected.

Patients considered vitamin D deficient had a risk of noninfectious uveitis more than twice that of their counterparts without vitamin D deficiency.

Investigators pointed out that spondyloarthritis (SpA) and Behçet’s disease are typical diseases that require the expertise of rheumatologists and ophthalmologists.

The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.

Experts from around the globe converged in San Francisco, California

The company has come into agreement with IQVIA Services Japan G.K. as well as AUROLAB.

According to the company, its RELIEF Phase 2b trial will evaluate the efficacy and safety of licaminlimab in moderate-to-severe dry eye disease, and further explore the potential of a genetic biomarker. Topline results are expected in mid-2024.

Austrian investigators recommend an interdisciplinary, rheumatologic–ophthalmologic approach to disease management